Personalizing Cancer Chemotherapy Based on Methylation and Germ-Line Mutational Analysis of BRCA-1
OwnerSven Olekinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for personalized diagnosing, prognosing, and treating of diseases, such as cancer, and in particular to a method for the personalized treatment of breast and/or ovarian cancer, based on a methylation and germ-line mutational analysis of the gene BRCA-1.
Claims17
A method for determining a patients' response to a chemotherapy for a tumor, comprising:
- a) determining the amount of methylation of the gene for BRCA-1, and
- b) determining germ-line mutations of the gene for BRCA-1, wherein an increase in the methylation is indicative for a lack of response of said patient to said treatment, if no germ-line mutations of the gene for BRCA-1 are detected.
A chemotherapy method comprising administering platinum salts, cisplatin, and/or paclitaxel to a tumor exhibiting an increased methylation of the gene BRCA-1 in a patient, wherein said chemotherapy is performed using increased local concentrations of platinum salts, cispiatin, and/or paclitaxel within individual treatment cycles, and wherein the tumor is selected from breast and/or ovarian tumors and/or metastases thereof.
Dependencies are inferred from the claim text.